Gilead Sciences has tapped Stacey Ma, PhD, as EVP, pharmaceutical development and manufacturing, a role in which she’ll report directly to chairman and CEO Daniel O’Day. She succeeds Taiyin Wang, PhD, who is retiring after nearly 30 years at Gilead, in the role.
Prior to arriving at Gilead, Ma was EVP and head of technical operations at Sana Biotechnology. She is also an American Institute for Medical and Biological Engineering fellow.
“With more than 25 years of diverse experience, Stacey has an impressive track record in the formulation and manufacture of medicines from pre-IND through commercialization. She brings deep expertise in multiple areas and across various modalities,” O’Day said in a statement. “Under Stacey’s leadership, and as we continue to diversify our portfolio, I am confident that Gilead will maintain a global reputation for excellence in the development, manufacture and supply of medicines.”
